Takano Koji, Yasufuku-Takano Junko, Morita Koji, Mori Shigetoshi, Takei Mao, Osamura Robert Yoshiyuki, Teramoto Akira, Fujita Toshiro
Department of Nephrology and Endocrinology, University of Tokyo Faculty of Medicine, Hongo Bunkyo-ku, Tokyo, Japan.
Clin Endocrinol (Oxf). 2009 May;70(5):769-75. doi: 10.1111/j.1365-2265.2008.03457.x. Epub 2008 Oct 21.
The GHRH-protein kinase A (PKA) signalling pathway is essential for cell proliferation and GH synthesis/secretion in somatotrophs. An inactivating mutation of PRKAR1A is one of the causes of somatotrophinoma in Carney complex (CNC). The basal PKA activity of somatotroph adenoma cells from CNC has not been evaluated because of a limited amount of available tissue.
This study examined how the PRKAR1A mutation affects the PKA signalling pathway in a human somatotrophinoma with a PRKAR1A mutation.
Somatotrophinoma cells from a 40-year-old male patient with CNC were used. The patient had a novel somatic heterozygous germline frameshift mutation (227delT) in PRKAR1A leading to a premature stop codon. The tumour showed loss of heterozygosity (LOH) at 17q23-24. Primary cultured adenoma cells were subjected to electrophysiological experiments to evaluate PKA signalling in individual cells.
GHRH did not increase the nonselective cation current or the voltage-gated calcium current in these adenoma cells, in contrast to nonadenomatous somatotroph cells in which these currents increase through the PKA pathway. Application of a PKA inhibitor inhibited the basal currents in these adenoma cells, results that were not observed in nonadenomatous somatotrophs. These data indicate that the basal currents are already increased and cannot be further increased by GHRH.
The results demonstrate that PKA is activated at the basal state in these adenoma cells. The data also show that both the nonselective cation current and the voltage-gated calcium current, vital regulators of GH secretion downstream of PKA, are maximally increased in these cells. These maximally increased currents probably account for the excessive GH secretion.
生长激素释放激素-蛋白激酶A(PKA)信号通路对于生长激素细胞的细胞增殖和生长激素合成/分泌至关重要。PRKAR1A的失活突变是卡尼综合征(CNC)中生长激素细胞瘤的病因之一。由于可用组织量有限,尚未评估CNC中生长激素腺瘤细胞的基础PKA活性。
本研究探讨PRKAR1A突变如何影响具有PRKAR1A突变的人类生长激素细胞瘤中的PKA信号通路。
使用来自一名40岁患有CNC的男性患者的生长激素细胞瘤细胞。该患者在PRKAR1A中存在一种新的体细胞杂合种系移码突变(227delT),导致过早的终止密码子。肿瘤在17q23-24处显示杂合性缺失(LOH)。对原代培养的腺瘤细胞进行电生理实验,以评估单个细胞中的PKA信号。
与非腺瘤性生长激素细胞不同,生长激素释放激素不会增加这些腺瘤细胞中的非选择性阳离子电流或电压门控钙电流,在非腺瘤性生长激素细胞中,这些电流通过PKA途径增加。应用PKA抑制剂可抑制这些腺瘤细胞中的基础电流,在非腺瘤性生长激素细胞中未观察到该结果。这些数据表明基础电流已经增加,生长激素释放激素不能使其进一步增加。
结果表明PKA在这些腺瘤细胞的基础状态下被激活。数据还显示,PKA下游生长激素分泌的重要调节因子非选择性阳离子电流和电压门控钙电流在这些细胞中均最大程度增加。这些最大程度增加的电流可能是生长激素过度分泌的原因。